FrancophonIA/ELRC3.0 huggingface dataset:
English: List of the names, pharmaceutical form(s), strength of the veterinary medicinal products, animal species, route of administration, applicant/marketing authorisation holder in the member states
Maltese: Lista tal-ismijiet, għamla farmaċewtika, qawwa tal-prodotti mediċinali veterinarji, speċi li fuqhom għandu jintuża lprodott, mnejn jingħata, detenturi tal-awtorizzazzjoni għattqegħid fis-suq fl-istat membru
English: 5 De Jong et al.: A pan-European survey of antimicrobial susceptibility towards human-use antimicrobial drugs among zoonotic and commensal bacteria isolated from healthy food producing animals.
Maltese: Stħarriġ pan-Ewropew ta' suxxettibilita antimikrobjali għall-mediċini antimikrobjali għall-użu mill-bniedem fost batterji żoonotiċi u commensal iżolati minn annimali b'saħħithom li jipproduċu l-ikel.
English: 4.4 Special warning for each target species.
Maltese: 4.5 Prekawzjonijiet speċjali għall-użu
English: Residue depletion data in chickens support a meat withdrawal period of 12 days when chickens are administered at 20 mg doxycycline hyclate/kg body weight/day for 4 days.
Maltese: Id-dejta dwar it-tneħħija ta' residwi fit-tiġieġ tappoġġa perjodu ta' rtirar ta' 12-il ġurnata għal-laħam meta t-tiġieġ jingħataw doża ta' 20 mg doxycycline hyclate/kg tal-piż tal-ġisem /ġurnata għal 4 ijiem.
English: = .... mg product per l drinking water
Maltese: = .... mg tal-prodott kull l ta' ilma tax-xorb
English: However, it is accepted that levels of resistance to tetracyclines reported in literature cannot be directly extrapolated to doxycycline, and that the greater liposolubility of doxycycline may explain why in vitro susceptibility of organisms has been maintained despite the emerging resistance to tetracycline.
Maltese: Madankollu, huwa aċċettat li l-livelli ta' reżistenza għat-tetraċiklini rrapportata fil-letteratura ma jistgħux jiġi direttament estrapolati għal doxycycline, u l-liposolubilità akbar ta' doxycycline tista' tispjega għaliex is-suxxebbilita in vitro ta' organiżmi nżammet minkejja r-reżistenza emerġenti għattetraċiklini.
English: Residue depletion data in chickens support a meat withdrawal period of 3 days when chickens are administered at 10 mg doxycycline hyclate/kg body weight/day for 4 days.
Maltese: Id-dejta dwar it-tneħħija ta' residwi fit-tiġieġ tappoġġa l-perjodu ta' rtirar ta' 3 ijiem għal-laħam meta t-tiġieġ jingħataw doża ta' 10 mg doxycycline hyclate/kg tal-piż tal-ġisem /ġurnata għal 4 ijiem.
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Aluminium Foil Sachet 100g (packed per 10)
Maltese: TAGĦRIF LI GĦANDU JIDHER FUQ IL-PAKKETT TA' BARRA Qartas tal-Folja tal-Aluminju tal-100g (ippakkjat għal kull 10)
English: Following administration of doxycycline hyclate at an actual dose of 21 mg/kg body weight to chickens mean plasma concentrations above 1 µg/ml were reached within 6 hours and lasted for 6 hours after cessation of medication.
Maltese: Wara l-għoti tad-doxycycline hyclate f'doża attwali ta' 21 mg/kg bw lit-tiġieġ il-medja ta' konċentrazzjonijiet fil-plażma ta' aktar minn 1 mg/ml kienu miksuba fi żmien 6 sigħat u dam għal 6 sigħat wara l-waqfien tal-medikazzjoni.
English: Doxycycline has a low affinity for forming complexes with calcium and studies have demonstrated that doxycycline scarcely affects skeleton formation.
Maltese: L-ebda effetti negattivi kienu osservati fit-tjur wara l-għoti ta' dożi terapewtiċi ta' doxycycline.
English: DATE OF REVISION OF THE TEXT To be completed nationally
Maltese: DATA TA' REVIŻJONI TAT-TEST
English: From 24 h up to 96 h after start of treatment the doxycycline plasma concentrations exceeded 2 µg/ml.
Maltese: Minn 24 siegħa sa 96 siegħa wara l-bidu tat-trattament lkonċentrazzjonijiet fil-plażma tad-doxycycline qabeż iż-2 g/ml.
English: No negative effects were observed in poultry after the administration of therapeutic doses of doxycycline.
Maltese: L-ebda effetti negattivi kienu osservati fit-tjur wara l-għoti ta' dożi terapewtiċi tad-doxycycline.
English: For the treatment of P. multocida, a dosage regimen of 10 mg/kg body weight for 4 or 5 days was agreed.
Maltese: Għall-kura ta' P. multocida, ġie miftiehem reġimen ta' dożaġġ ta' 10 mg/kg tal-piż tal-ġisem għal 4 jew 5 ijiem.
English: 4.5 Special precautions for use
Maltese: 2. GĦAMLA KWALITATTIVA
English: In addressing the dosing regimen the Marketing Authorisation Holder has not discussed Pharmacokinetic/Pharmacodynamic in terms of a parameter that will limit the development of resistance.
Maltese: Fl-indirizzar tar-reġimen ta' dożaġġ is-Sid tal-Awtorizzazzjoni tal-Kummerċjalizzazzjoni ma ddiskutiex il-Farmakokinetika/Farmakodinamika f'termini ta' parametru li jillimita l-iżvilupp ta' reżistenza.
English: The main sections of disharmony of the existing SPCs were:
Maltese: Is-sezzjonijiet ewlenin ta' diżarmonijia tal-SPCs eżistenti kienu:
English: Doxycycline is bacteriostatic and acts by inhibiting protein synthesis intracellularly by binding to the 30-S subunit of the bacterial ribosome.
Maltese: Doxycycline huwa batterjostatiku u jaġixxi billi jimpedixxi s-sintesi tal-proteini fiċ-ċelloli billi jeħel mas-sottounità 30-S tar-ribosoma batterika.
English: • Chickens (broiler, pullet, breeder): Where clinical disease is present in the flock, to reduce mortality, morbidity and clinical signs and to reduce lesions due to Pasteurella multocida or to reduce morbidity and lesions in respiratory infections caused by O. rhinotracheale.
Maltese: Fejn marda klinika hija preżenti fil-qatgħa, biex tnaqqas il-mortalità, il-morbożità u s-sinjali kliniċi u biex tnaqqas il-leżjonijiet minħabba Pasteurella multocida jew biex tnaqqas il-morbożità u l-leżjonijiet fl-infezzjonijiet respiratorji kkawżati minn O. rhinotracheale.
English: • Withdrawal periods.
Maltese: • Il-perjodi tal-irtirar.
English: Inform your veterinary surgeon if adverse reactions occur that are not stated.
Maltese: Informa lit-tabib veterinarju tiegħek jekk irreazzjonijiet avversi jseħħu li mhumiex mistqarra.
English: Use at minimum concentrations of 200 mg powder per litre drinking water in areas with hard alkaline drinking water (hardness above 10.2 °d and pH more than 8.1).
Maltese: Uża f'konċentrazzjonijiet minimu ta' 200 mg trab għal kull litru ilma tax-xorb f'postijiet bl-ilma tax-xorb alkalin iebes (ebusija ‘l fuq minn 10.
English: The solubility of the product is pH dependent and will precipitate if mixed in alkaline solution.
Maltese: Is-solubilità tal-prodott hija pH dipendenti u tippreċipita jekk imħallat f'taħlita alkalina.
English: Ref.: EMEA/748861/2009 EMEA/H/C/558/II/29
Maltese: EMEA/748861/2009 EMEA/H/C/558/II/29
English: London, 19 November 2009 Doc.
Maltese: Londra, 19 ta' Novembru 2009 Dok. ta' Ref.:
English: What is Erbitux?
Maltese: X'inhu Erbitux?
English: After considering the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the refusal of the marketing authorisation on 19 November 2009.
Maltese: Wara li kkunsidra r-raġunijet għal din it-talba, isCHMP reġa' eżamina l-opinjoni inizjali u kkonferma r-rifjut tal-awtorizzazzjoni għat-tqegħid fis-suq fid-19 ta' Novembru 2009.
English: Erbitux is a solution for infusion (drip into a vein) that contains the active substance cetuximab.
Maltese: Erbitux huwa soluzzjoni għall-infużjoni (dripp ġo vina) li fiha s-sustanza attiva cetuximab.
English: Erbitux has been authorised since June 2004.
Maltese: Erbitux ilu awtorizzat minn Ġunju 2004.
English: What was Erbitux expected to be used for?
Maltese: Għalxiex kien mistenni li jintuża Erbitux?
English: On 23 July 2009, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of a change to the marketing authorisation for the medicinal product Erbitux.
Maltese: Fit-23 ta' Lulju 2009, il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) adotta opinjoni negattiva, fejn irrakkomanda r-rifjut għal modifika fl-awtorizzazzjoni għat-tqegħid fis-suq għal prodotti mediċinali Erbitux.
English: The company presented the results of two main studies involving a total of 1,801 adults with advanced, metastatic or recurrent non-small cell lung cancer who had not been treated before.
Maltese: Il-kumpanija ppreżentat ir-riżultati ta' żewġ studji ewlenin li jinvolvu total ta' 1,801 adult b'kanċer tal-pulmun taċ-ċelloli mhux żgħar avvanzat, metastatiku jew rikorrenti li ma kinux ġew ittrattati qabel.
English: Erbitux was to be used in combination with platinum-based chemotherapy (a combination of anticancer medicines that includes a medicine such as cisplatin or carboplatin).
Maltese: Erbitux kellu jintuża flimkien ma' kimoterapija bbażata fuq il-platinum (taħlita ta' mediċini kontra l-kanċer li tinkludi mediċina bħal cisplatin jew carboplatin).
English: In July 2009, the CHMP was concerned that the benefits of adding Erbitux to standard platinum-based chemotherapy were modest in terms of survival times, and that the medicine did not have a convincing effect on how long patients lived without their cancer getting worse.
Maltese: F'Lulju 2009, is-CHMP kien imħasseb li l-benefiċċji taż-żieda ta' Erbitux mal-kimoterapija standard ibbażata fuq il-platinum kienu modesti f'termini ta' żminijiet ta' sopravvivenza, u li l-mediċina ma kellhiex konvinċenti fuq kemm damu jgħixu l-pazjenti mingħajr ma l-kanċer tagħhom imur għallagħar.
English: These ‘subgroup analyses' attempted to identify a group of patients that would benefit from treatment.
Maltese: Dawn ‘l-analiżi tas-sottogruppi' ippruvaw jidentifikaw grupp ta' pazjenti li setgħu jibbenefikaw mit-trattament.
English: Severe side effects were seen in some lung cancer patients who received Erbitux - these were similar to the side effects seen in patients treated with Erbitux for other types of cancer.
Maltese: Dehru effetti sekondarji severi f'xi pazjenti b'kanċer tal-pulmun li ngħataw Erbitux - dawn kienu simili għall-effetti sekondarji li dehru f'pazjenti li ġew ittrattati b'Erbitux għal tipi ta' kanċer oħrajn.
English: Erbitux can be used when the cancer is locally advanced (when the tumour has grown but has not spread), recurrent (when it has come back after previous treatment) or metastatic.
Maltese: Erbitux jista' jintuża meta l-kanċer ikun avvanzat lokalment (meta t-tumur ikun kiber iżda ma jkunx infirex), rikorrenti (meta jkun reġa' feġġ wara trattament preċedenti) jew metastatiku.
English: The company informed the CHMP that there are no consequences for patients currently included in clinical trials with Erbitux.
Maltese: Il-kumpanija għarrfet lis-CHMP li ma kienx hemm konsegwenzi għall-pazjenti li attwalment kienu involuti fi provi kliniċi b'Erbitux.
English: • metastatic cancer of the colon or rectum (large intestine).
Maltese: • kanċer taċ-‘ċelloli skwamużi' tar-ras u tal-għonq.
English: The full European Public Assessment Report for Erbitux is available here.
Maltese: Ir-Rapport ta' Valutazzjoni Pubblika Ewropew sħiħ għal Erbitux huwa disponibbli hawnhekk.
English: These types of cancer affect the cells of the lining of the mouth or the throat, or of organs such as the larynx (voice box).
Maltese: Dawn it-tipi ta' kanċer jaffettwaw iċ-ċelloli talkisi tal-ħalq jew tal-gerżuma, jew tal-organi bħal-larinġi (il-kaxxa tal-vuċi).
English: In both studies, the combination of Erbitux with platinum-based chemotherapy was compared with platinum based chemotherapy without Erbitux.
Maltese: kimoterapija bbażata fuq il-platinum mingħajr Erbitux.
English: It was to be used in patients who had not been treated before, when the tumour cells had a protein on their surface called epidermal growth factor receptor (EGFR).
Maltese: Kien jintuża f'pazjenti li ma kinux ġew ittrattati qabel, meta ċ-ċelloli tat-tumur kellhom proteina fuq il-wiċċ tagħhom imsejħa riċettur tal-fattur tattkabbir epidermali (epidermal growth factor receptor - EGFR).
English: What were the major concerns that led the CHMP to recommend the refusal of the change to the marketing authorisation?
Maltese: X'kien it-tħassib ewlieni li wassal lis-CHMP sabiex jirrakkomanda r-rifjut tal-modifika flawtorizzazzjoni għat-tqegħid fis-suq?
English: Erbitux was also expected to be used to treat ‘non-small cell' lung cancer that was advanced (had started to spread) or metastatic.
Maltese: Erbitux kien mistenni li jintuża wkoll għat-trattament tal-kanċer tal-pulmun taċ-‘ċelluli mhux żgħar' li kien avvanzat (kien beda jinfirex) jew metastatiku.
English: Ref.: EMA/756630/2009 EMEA/H/C/264
Maltese: Dok. ta' ref.:EMEA/756630/2009 EMEA/H/C/264
English: Agenerase amprenavir EPAR summary for the public
Maltese: Agenerase amprenavir Sommarju tal-EPAR għall-pubbliku
English: It is available as cream capsules (50 and 150 mg) and as an oral solution (15 mg/ml).
Maltese: Huwa disponibbli f'kapsuli lewn ilkrema (50 u 150 mg) u bħala soluzzjoni orali (15 mg/ml).
English: The active substance in Agenerase, amprenavir, is a protease inhibitor.
Maltese: Is-sustanza attiva f'Agenerase, amprenavir, hija inibitur tal-proteażi.
English: Agenerase is a medicine that contains the active substance amprenavir.
Maltese: Agenerase huwa mediċina li fiha s-sustanza attiva amprenavir.
English: The most common side effects with Agenerase (seen in more than 1 patient in 10) are hypercholesterolaemia (high blood cholesterol levels), headache, diarrhoea, flatulence (gas), nausea (feeling sick), vomiting, rash and fatigue (tiredness).
Maltese: L-effetti sekondarji l-aktar komuni b'Agenerase (li dehru f'pazjent 1 minn 10) huma iperkolestoremija (livelli ta' kolesterol għoljin), uġigħ ta' ras, dijarrea, flatulenza (gass), nawżea (dardir), remettar, raxx u għeja.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Agenerase to Glaxo Group Limited on 20 October 2000.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Agenerase lil Glaxo Group Limited fl-20 ta' Ottubru 2000.
English: If ritonavir is not used, Agenerase is taken at a higher dose (1,200 mg twice a day).
Maltese: Jekk ma jintużax ritonavir, Agenerase jittieħed f'doża ogħla (1,200 mg darbtejn kuljum).
English: In adults, Agenerase capsules are usually given with low-dose ritonavir (another antiviral medicine).
Maltese: Fl-adulti, il-kapsuli ta' Agenerase ġeneralment jingħataw ma' doża baxxa ta' ritonavir (mediċina antivirali oħra).
English: What is the risk associated with Agenerase?
Maltese: X'inhu r-riskju assoċjat ma' Agenerase?
English: Agenerase is used in combination with other antiviral medicines to treat patients over four years of age who are infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Maltese: Agenerase jintuża flimkien ma' mediċini antivirali oħra fit-trattament ta' adulti u tfal ta' età ‘l fuq minn erba' snin infettati mill-vajrus tal-immunodefiċjenza umana tat-tip 1 (HIV-1), vajrus li jikkawża s-sindromu minn immunodefiċjenza akkwiżita (AIDS).
English: The recommended dose of Agenerase for patients over 12 years of age is 600 mg twice a day, taken with 100 mg ritonavir twice a day and with other antiviral medicines.
Maltese: Id-doża ta' Agenerase rakkomandata għal pazjenti ta' età ‘l fuq minn 12-il sena hija 600 mg darbtejn kuljum, meħuda ma' 100 mg ritonavir darbtejn kuljum u ma' mediċini antivirali oħra.
English: Agenerase without ritonavir has also been compared with placebo (a dummy treatment) and with invirase (another protease inhibitor) in 736 HIV-infected adults who had not previously been treated with protease inhibitors.
Maltese: Agenerase bla ritonavir ġie mqabbel ukoll ma' plaċebo ( trattament finta) u b'invirase (inibitur proteażi ieħor) f'736 adulti infettati li ma ġewx ittratti preċedentement b'inibituri tal-proteażi.
English: Agenerase without ritonavir has also been studied in 268 HIV-infected children and adolescents aged between six months and 18 years, all of whom had previously taken treatment for HIV infection, and 135 of whom had been treated with protease inhibitors.
Maltese: Agenerase mingħajr ritonavir, ġie studjat ukoll f'268 tfal u adoloxxenti infettati mill-HIV li 135 minnhom kienu ġew ittrattati preċedentement b'inibituri tal-proteażi.
English: As with other anti-HIV medicines, patients taking Agenerase may be at risk of lipodystrophy (changes in the distribution of body fat), osteonecrosis (death of bone tissue) or immune reactivation syndrome (symptoms of infection caused by the recovering immune system).
Maltese: Bħal għal mediċini oħra ta' kontra l-HIV, il-pazjenti ttrattati b'Agenerase jista' jkollhom riskju ta' lipodistrofija (bidliet fid-distribuzzjoni tax-xaħam fid-demm), osteonekrożi (mewt ta' tessut talgħadam) jew sindromu tar-riattivazzjoni immunitarja (sintomi ta' infezzjoni kkawżati minn sistema immunitarja li tkun qed tirkupra).
English: Why has Agenerase been approved?
Maltese: Għaliex ġie approvat Agenerase?
English: Ritonavir is another protease inhibitor that is used as a ‘booster'.
Maltese: Ritonavir hu inibitur tal-proteażi ieħor li jintuża bħala ‘booster'.
English: Because amprenavir is less easily absorbed with the oral solution than with the capsules, the two formulations are not interchangeable on a milligram-for-milligram basis.
Maltese: Billi amprenavir f'soluzzjoni orali huwa assorbit inqas faċilment meta mqabbel mal-kapsuli; iż-żewġ formulazzjonijiet ma jistgħux jinbiddlu ma' xulxin fuq bażi ta' milligramm għal kull milligramm.
English: How has Agenerase been studied?
Maltese: Kif ġie studjat Agenerase?
English: In adults who had taken protease inhibitors in the past, Agenerase boosted with ritonavir was as effective as other protease inhibitors in reducing viral loads after 16 weeks of treatment: around two thirds of the patients in both groups had viral loads below 400 copies/ml.
Maltese: Fl-adulti li kienu ħadu inibituri tal-proteażi fil-passat, Agenerase bil-booster ritonavir kien effikaċi daqs inibituri tal-proteażi oħrajn fit-tnaqqis tat-tagħbija virali wara 16-il ġimgħa ta' trattament: madwar żewġ terzi tal-pazjenti fiż-żewġ gruppi rreġistraw tagħbija virali inqas minn 400 kopja/ml.
English: Agenerase boosted with ritonavir must not be taken by patients who have severe problems with their liver, or by patients taking rifampicin (used to treat tuberculosis) or medicines that are broken down in the same way as ritonavir, such as flecainide and propafenone (used to correct irregular heartbeat).
Maltese: Agenerase bil-booster ritonavir lanqas ma għandu jittieħed minn pazjenti li jbatu minn problemi gravi fil-fwied jew minn pazjenti li qegħdin jagħmlu użu mir-rifampiċina (rifampicin, użata fit-trattament tat-tuberkulożi) jew mediċini li jiġu metabolizzati bl-istess mod bħal ritonavir, bħalma huma flecainide u propafenone (użati biex jikkoreġu l-aritmija kardijaka [taħbit irregolari tal-qalb]).
English: Agenerase boosted with low-dose ritonavir has been compared with other protease inhibitors in 206 adults who had taken protease inhibitors in the past.
Maltese: Agenerase mal-booster ta' ritonavir f'doża baxxa tqabbel ma' inibituri tal-proteażi oħra f'206 adulti ttrattati fil-passat bl-inibituri tal-proteażi.
English: Of these, 43 had HIV that was resistant to four other protease inhibitors.
Maltese: Fost dawn, 43 kellhom HIV reżistenti għal erba' inibituri talproteażi oħra.
English: For the full list of all side effects reported with Agenerase, see the Package Leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji rrappurtati b'Agenerase, ara l-Fuljett ta' Tagħrif.
English: Taking Agenerase with ritonavir should be avoided in children.
Maltese: Il-Kumitat irrakkomanda li Agenerase jingħata awtorizzazzjoni għat-tqegħid fis-suq.
English: How is Agenerase used?
Maltese: Għal xiex jintuża Agenerase?
English: Other information about Agenerase:
Maltese: Aktar tagħrif dwar Agenerase:
English: Agenerase, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Maltese: Agenerase, meħud flimkien ma' mediċini antivirali oħra, inaqqas l-ammont ta' HIV fid-demm u jżommu f'livell baxx.
English: Agenerase does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Maltese: Agenerase ma jfejjaqx infezzjoni mill-HIV jew tal-AIDS, iżda jista' jittardja lħsara prodotta lis-sistema immunitarja u l-iżvilupp ta' infezzjonijiet u mard assoċjat mal-AIDS.
English: In children aged between four and 12 years and in patients who weigh less than 50 kg, the recommended dose of Agenerase depends on body weight.
Maltese: Fit-tfal f'età bejn erbgħa u 12-il sena u fil-pazjenti li jiżnu inqas minn 50 kg, id-doża rakkomandata ta' Agenerase tiddependi mill-piż tal-ġisem.
English: Treatment with Agenerase should be started by a doctor who has experience in the management of HIV infection.
Maltese: It-terapija b'Agenerase għandha tinbeda minn tabib li jkollu esperjenza fit-trattament tal-infezzjoni mill-HIV.
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Agenerase benefits are greater than its risks, but noted that the benefit of Agenerase taken with ritonavir has not been demonstrated in patients who have not taken protease inhibitors in the past.
Maltese: Il-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) iddeċieda li l-benefiċċji ta' Agenerase huma ogħla mir-riskji, madankollu l-Kumitat nnota li l-benefiċċji ta' Agenerase meħud ma' ritonavir ma ntwerewx f'pazjenti li fil-passat ma kinux ħadu inibituri tal-proteażi.
English: The dose of Agenerase should be reduced in patients who have problems with their liver, and it should be taken without ritonavir by patients who have severe liver problems.
Maltese: Fil-pazjenti li jbatu minn problemi bil-fwied, id-doża ta' Agenerase għandha titnaqqas u fil-pazjenti li jbatu minn problemi gravi fil-fwied il-mediċina għandha tingħata mingħajr ritonavir.
English: It may harm them,
Maltese: tibdil fit-taħbit tal-qalb, insuffiċjenza tal-qalb.
English: Capsules
Maltese: Kapsuli
English: Oral Solution Pfizer Service Company Hoge Wei 10
Maltese: Soluzzjoni orali Pfizer Service Company Hoge Wei 10
English: 473 ml oral solution
Maltese: 473 ml ta' soluzzjoni orali
English: It may harm them, even if their signs of illness are the same as yours.
Maltese: • Disturbi fir-ritmu tal-qalb, taħbit tal-qalb aktar mgħaġġel, pressjoni baxxa, pressjoni għolja, tibdil fit-taħbit tal-qalb, insuffiċjenza tal-qalb.
English: See section 6.6 for information on administration.
Maltese: Ara sezzjoni 6.6 għal aktar informazzjoni ta' kif jingħata.
English: * Alanine aminotransferase increased (ALT) and aspartate aminotransferase increased (AST).
Maltese: *Żieda fl-alanine aminotransferase (ALT) u żieda fl-aspartate aminotransferase (AST)
English: Capsules content: Lactose monohydrate Maize starch Talc
Maltese: Kontenut tal-kapsula: Lactose monohydrate Maize starch Talkum
English: Supplementary dose following haemodialysis (mg) 25 (1.25 ml)
Maltese: Doża supplimentari wara ħemodijaliżi (mg) 25 (1.25 ml)
English: Pfizer Service Company, Hoge Wei 10, B1930 Zaventem, Belgium
Maltese: Pfizer Service Company, Hoge Wei 10, B1930
English: Pfizer Manufacturing Deutschland GmbH, Betriebsstātte Freiburg, Mooswaldallee 1, 79090 Freiburg, Germany.
Maltese: Pfizer Manufacturing Deutschland GmbH, Betriebsstātte Freiburg, Mooswaldallee 1, 79090 Freiburg, Il-Ġermanja.
English: Black iron oxide (E172) Propylene glycol Potassium hydroxide
Maltese: Iron oxide iswed (E172) Propylene glycol Potassium hydroxide
English: • Vertigo, problems with balance, fall.
Maltese: • Vertigo, problemi fil-bilanċ, waqgħat
English: Remove the syringe from the bottle/PIBA (Figure 6).
Maltese: Neħħi s-siringa minn ġol-flixkun/PIBA (Figura 6).
English: Lyrica may be taken with oral contraceptives.
Maltese: Lyrica jista' jittieħed ma' kontraċettivi orali.
English: Ελλάδα Pfizer ΕΛΛΑΣ Α.Ε.Τηλ.
Maltese: Twaqqif ta' pregabalin jista jfejjaq ir-reazzjoni.
English: BID or TID
Maltese: BID jew TID